Free cash flow · 2023–2025

Caris Life Sciences free cash flow

$66.9M+$321M · FY2025

Caris Life Sciences (CAI) reported $66.9M in free cash flow for fiscal 2025, +$321M from the year before.

−$298M2023−$254M2024$66.9M2025
Caris Life Sciences — Free cash flow, 2023–2025
Fiscal yearFree cash flowChangeFiling
FY2025$66.9M+$321MDerived
FY2024−$254M+$44.8MDerived
FY2023−$298M—Derived

Free cash flow — Free cash flow is operating cash flow minus capital expenditure: what is left once the company has paid to maintain and expand its asset base. We calculate it from two lines in the same filing, and a company is only ranked here if it reported both.

Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026

Calculated from two reported figures, so it has no single filing of its own.

Free cash flow at companies of similar size

Full ranking by free cash flow →

Cite this page

Ready-made references for the figures on this page, as published on September 25, 2026.

Wikipedia

{{cite web |title=Caris Life Sciences free cash flow |url=https://companiesranked.com/en/company/caris-life-sciences/free-cash-flow |website=CompaniesRanked |date=2026-09-25 |language=en}}

APA 7

CompaniesRanked. (September 25, 2026). Caris Life Sciences free cash flow. CompaniesRanked. https://companiesranked.com/en/company/caris-life-sciences/free-cash-flow

BibTeX

@misc{companiesranked-en-company-caris-life-sciences-free-cash-flow-2026,
  author       = {{CompaniesRanked}},
  title        = {{Caris Life Sciences free cash flow}},
  year         = {2026},
  howpublished = {\url{https://companiesranked.com/en/company/caris-life-sciences/free-cash-flow}},
  note         = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
  urldate      = {2026-09-25}
}

The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.

← Caris Life Sciences overview